Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H10FN3 |
Molecular Weight | 262.2716 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[18F]C1=CC=C(C=N1)C2=CC=C3C(NC4=C3C=NC=C4)=C2
InChI
InChIKey=GETAAWDSFUCLBS-SJPDSGJFSA-N
InChI=1S/C16H10FN3/c17-16-4-2-11(8-19-16)10-1-3-12-13-9-18-6-5-14(13)20-15(12)7-10/h1-9,20H/i17-1
Molecular Formula | C16H10FN3 |
Molecular Weight | 262.2716 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Flortaucipir (18F-AV-1451, also known as 18F-T807) is a highly selective positron emission tomography (PET) imaging agent targeting paired helical filament (PHF)-tau in the brain. This tracer is studying for clinical assessment in patients with various tauopathies, including Alzheimer's disease, as well as in healthy subjects.
CNS Activity
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
[(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. | 2013 Nov |
|
Synthesis and quality control of [(18) F]T807 for tau PET imaging. | 2016 Aug |
|
Kinetics of the Tau PET Tracer 18F-AV-1451 (T807) in Subjects with Normal Cognitive Function, Mild Cognitive Impairment, and Alzheimer Disease. | 2016 Oct |
|
Tau-PET Binding Distinguishes Patients With Early-stage Posterior Cortical Atrophy From Amnestic Alzheimer Disease Dementia. | 2017 Apr-Jun |
|
Quantification of Tau Load Using [18F]AV1451 PET. | 2017 Dec |
|
Region-Specific Association of Subjective Cognitive Decline With Tauopathy Independent of Global β-Amyloid Burden. | 2017 Dec 1 |
|
Tau PET imaging: present and future directions. | 2017 Feb 20 |
|
Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. | 2017 Jul 1 |
|
Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. | 2017 Mar 1 |
|
18 F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. | 2017 Oct |
|
18F-Flortaucipir PET/MRI Correlations in Nonamnestic and Amnestic Variants of Alzheimer Disease. | 2018 Feb |
Patents
Sample Use Guides
Flortaucipir PET images were acquired for 20 min, as four 5-min frames, beginning 80 min after injection of 370 MBq flortaucipir. On a separate day, subjects underwent a florbetapir PET scan for 10 min, as two 5-min frames, beginning 50 min after injection of 370 MBq florbetapir F18.
Route of Administration:
Parenteral
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Oct 21 22:49:52 UTC 2019
by
admin
on
Mon Oct 21 22:49:52 UTC 2019
|
Record UNII |
T1JP1KYU9O
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
70957463
Created by
admin on Mon Oct 21 22:49:52 UTC 2019 , Edited by admin on Mon Oct 21 22:49:52 UTC 2019
|
PRIMARY | |||
|
1522051-90-6
Created by
admin on Mon Oct 21 22:49:52 UTC 2019 , Edited by admin on Mon Oct 21 22:49:52 UTC 2019
|
PRIMARY | |||
|
10203
Created by
admin on Mon Oct 21 22:49:52 UTC 2019 , Edited by admin on Mon Oct 21 22:49:52 UTC 2019
|
PRIMARY | |||
|
CHEMBL3546271
Created by
admin on Mon Oct 21 22:49:52 UTC 2019 , Edited by admin on Mon Oct 21 22:49:52 UTC 2019
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->RADIOLIGAND |
Images aggregates
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |